September 2008 ASBMR Meeting: Dr. Abrahamsen Asserts Atypical Fractures Of Femur Are Not Triggered By Fosamax (Posted by Tom Lamb at DrugInjuryWatch.com ) In late June 2008 we learned that one type of femoral stress fracture (simple, transverse) may be caused by long term use of the popular bisphosphonate Fosamax . Drs. Dean G. Lorich and Joseph M. Lane of NewYork-Presbyterian Hospital/Weill Cornell Medical Center presented information about this possible new Fosamax side effect in the latest issue of the Journal of Orthopaedic Trauma. About three months later, however, a Danish researcher said said that such atypical fractures of the femur do not appear to be triggered by Fosamax (alendronate). In more detail, in mid-September 2008 at the American Society for Bone and Mineral Research (ASBMR) meeting in Montreal, Bo Abrahamsen, Ph.D., of Copenhagen University Hospital Gentofte, asserted that patients treated with the anti-osteoporosis drug Fosamax apparently had a higher risk of these atypical fractures (as well as fractures of any kind) to start with for the simple reason that they were taking a drug known to reduce the risk of hip fractures. For elaboration on Dr. Abrahamsen's position we turn to the September 15, 2008 Medpage Today article, "ASBMR: Alendronate Exonerated in 'Atypical' Femoral Fractures" : The three case reports earlier this year suggested that a common factor in patients with subtrochanteric or proximal diaphyseal ...
Anytime
